Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.

about

Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.

Item

http://www.wikidata.org/entity/Q40274682

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Micronized fenofibrate: a usef ...... syndrome and Type 2 diabetes.

@en

type

Item

label

Micronized fenofibrate: a usef ...... syndrome and Type 2 diabetes.

@en

prefLabel

Micronized fenofibrate: a usef ...... syndrome and Type 2 diabetes.

@en

P1476

Micronized fenofibrate: a usef ...... syndrome and Type 2 diabetes.

@en

P2093

Anthony C Keech

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Ansquer

http://www.w3.org/2001/XMLSchema#string

P2860

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

National trends in statin use by coronary heart disease risk category

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

P304

635-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14796678.2.6.635

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stuart M. Grieve

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19804254

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

metabolic syndrome

dyslipidemias